Measurements of aminoglycosides by an agar disk diffusion assay are inhibited by heparin in a dose-dependent way. When assayed by a homogeneous immunoassay, this was only evident for tobramycin. This indicates that specimens for aminoglycoside measurement should not be obtained in heparinized tubes. When heparin is used clinically as an anticoagulant, the amount in blood does not reach levels that affect the aminoglycoside activity.
Measurements of aminoglycosides by an agar disk diffusion assay are inhibited by heparin in a dose-dependent way. When assayed by a homogeneous immunoassay, this was only evident for tobramycin. This indicates that specimens for aminoglycoside measurement should not be obtained in heparinized tubes. When heparin is used clinically as an anticoagulant, the amount in blood does not reach levels that affect the aminoglycoside activity.
Heparin has been reported to inhibit the measurement of gentamicin concentrations by an agar diffsion procedure (6) . This was confirmed, and it was also shown that heparin inhibited gentamicin measurements with a newly developed rapid luciferase method (1, 2) . In this report the effects of heparin on gentamicin, a-ikacin, netilmicin, and tobramycin were studied, and the effect of sampling in clinical practice with heparinized capillaries compared with nonheparinized tubes was evaluated.
MATERIALS Samples of venous blood in nonheparinized tubes and skin puncture samples in heparinized capillaries (Drummond Scientific Co.) were taken simultaneously.
Determination of aminoglycosides. The aminoglycoside concentrations were determined by an agar disk diffusion assay with E. coli LU14 as the test strain and antibiotic medium no. 2 (Oxoid) (pH 7.9) as the assay medium. E. coli LU14 is resistant to most antibiotics encountered in combination with aminoglycosides (3). The aminoglycoside concentrations in the clinical samples were determined only by the agar disk diffusion assay, whereas in all other samples they were also determined by a homogeneous enzyme immunoassay (EMIT; Syva Corp., Palo Alto, Calif.). Netilmicin was determined by an EMIT gentamicin assay kit. It is not possible to determine amikacin by a commercially available EMIT kit. All assays were performed in duplicate.
RES3ULTS
The growth of E. coli LU14 was not affected by heparin itself. The inhibitory effect ofheparin on the recovery of amikacin, gentamicin, netilmicin, and tobramycin (8 j&g/ml) in the presence of increasing amounts of heparin in pooled human serum, as determined by the agar disk diffusion assay, is shown in Fig. 1 . The inhibition increased quantitatively at 62.5 IU of heparin per ml. Similar results were obtained with 16 and 4.0 ,ug of the aminoglycosides per ml. The inhibition of tobramycin (8 ,g/ml) when assayed by EMIT was more pronounced, and started at a lower concentration of heparin, whereas gentamicin and netilmicin were less affected (Fig.  1) . The results presented in Fig. 1 are the mean values of five experiments with the agar disk diffusion assay and two experiments with EMIT. The standard deviation ranged between 0.9 and 10.1% (mean, 5.0%) for the agar disk diffusion assay and between 0.7 and 8.6% (mean, 3.7%) for EMIT.
The results from sampling aminoglycosides (8 ,ug/ml) with heparinized capillaries are given in Table 1 . The recovery of aminoglycosides with EMIT was higher than with the agar disk diffusion assay, except for tobramycin, where the recovery was much lower.
The inhibitory effect of heparin on the aminoglycoside activity was reversible by dilution ( Table 2) . Nilsson (2) . In the present study similar results were obtained with amikacin, netilmicin, and tobramycin when the drug concentrations were determined by the agar disk diffusion assay. However, when assayed by EMIT the dose-dependent inhibition was evident only for tobramycin. Heparin is highly anionic (7) , and the aminoglycosides exist as positively charged molecules at the pH range 5 to 8 (8) . The masking of the aminoglycoside activity by heparin is probably an inhibition by ionic interaction, rather than an inactivation, since the effect may be reversed by dilution. This might explain why gentamicin and netilmicin are less affected when assayed by EMIT than when assayed by the agar disk diffusion assay. In the former assay the samples are diluted 1:108 in tris(hydroxymethyl)aminomethane buffer, whereas they are undiluted in the latter assay. In contrast to the other aminoglycosides, tobramycin was determined to be affected when assayed by both methods. The immunoassay of gentamicin and netilmicin was performed with a gentamicin assay kit, and tobramycin was assayed with a tobramycin assay kit. Possibly heparin interacts with the different aminoglycoside antibodies to various extents.
When heparin is used clinically, effective anticoagulation is achieved at 1 to 2 IU/ml (5) and the amount in blood does not exceed 10 IU/ml (4). Our results show that aminoglycoside activity is not affected at these concentrations of heparin. Thus heparin treatment is unlikely to interfere with aminoglycoside therapy.
In vitro sampling and clinical sampling with heparinized capillaries lowered the aminoglycoside activity to the same degree, as determined by the agar disk diffusion assay. The smallest amount of heparin in the capillary tubes was 3 IU. The tubes contained 60 pl, which gave a heparin concentration of 50 IU/ml. The amount of heparin in the tubes differs, and the manufacturer cannot predict the highest amount of heparin in the tubes. The sample volume obtained in the capillary also affects the concentrations of heparin reached after centrifugation of the tube. Furthermore, the progressive inhibition of aminoglycoside activity at rising concentrations of heparin ( Fig. 1) indicates that the lowest concentration of heparin obtainable in the capillaries (50 IU/ml) gives approximately the same degree of inhibition as sampling with heparinized capillaries.
The fact that heparin and not sampling differences accounts for the inhibition of aminoglycoside activity in the heparinized clinical specimens is evident from the results presented. Thus the outcome of the clinical samples and the in vitro sampling with heparinized capillaries shows that the level of aminoglycosides will be underestimated when samples are submitted for assay in heparinized tubes or capillaries.
